基于网络药理学研究升陷汤治疗肺纤维化的作用机制
The Mechanisms of Sheng Xian Tang against Pulmonary Fibrosis: A Network Pharmacology-Based Study
DOI: 10.12677/TCM.2022.113070, PDF,    科研立项经费支持
作者: 刘馨媛:延边大学,吉林 延吉;中国医学科学院北京协和医院中医科,北京;贾一凡, 朴元林:中国医学科学院北京协和医院中医科,北京
关键词: 升陷汤肺纤维化网络药理作用机制Sheng Xian Tang Pulmonary Fibrosis Network Pharmacology Mechanism
摘要: 目的:为了挖掘升陷汤的有效成分、预测其潜在功能靶标,通过网络药理学探讨升陷汤治疗肺纤维化的作用机制。方法:利用TCMSP数据库筛选升陷汤活性成分及其作用的潜在靶点;通过GeneCards数据库检索与肺纤维化疾病相关的靶点;将疾病相关靶点映射到化合物潜在靶点中,获取药物–疾病共同靶点,并将信息导入Cytoscape4.7.0软件和STRING在线分析平台分别制作网络图和PPI图,再进行KEGG和GO富集分析。结果:共筛选出69个活性成分以及101个关键靶点,涉及PI3K-Akt signaling pathway、Fluid shear stress and atherosclerosis、AGE-RAGE signaling pathway in diabetic complications等信号通路。结论:网络药理学研究揭示升陷汤可通过多成分–多靶点–多途径共同调控肺纤维化的物质基础和作用机制,为升陷汤的临床应用提供了理论基础和科学依据。
Abstract: Background: To investigate the main compounds, the underlying functional targets and the me- chanism of Sheng Xian Tang (upraise the sunken decoction, SXT) formula treating pulmonary fibrosis (PF) through network pharmacology analysis. Methods: The main compounds and targets of SXT were mainly collected from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). PF relating targets were collected from the GeneCards databases. Subsequently, targets were mapped into the compounds to obtain a compound-disease complex, and then employ STRING online analysis platform and Cytoscape4.7.0 software to generate protein-protein interaction (PPI) networks. Then the related pathways and correlation analysis were explored by the Kyoto Encyclopedia and Genomes (KEGG) and Gene Ontology (GO) analysis. Results: The database results showed that there were 69 active compounds in SXT, and 101 targets were screened out for PF treatment. Network analysis indicated that the main targets of the main active components of SXT were target genes such as PI3K-Akt, Fluid shear stress and atherosclerosis, and AGE-RAGE signaling pathways. PI3K-Akt signaling pathway, Fluid shear stress and atherosclerosis, AGE-RAGE signaling pathway in diabetic complications and HIF-1 signaling pathway, etc. Conclusions: This study helped to validate the material basis and underlying mechanism of SXT for treating PF in a multi-components, multi-targets, and multi-pathways pattern. Additionally, this study provides a theoretical basis and scientific proof for the reasonable application of SXT in the clinical practice for PF.
文章引用:刘馨媛, 贾一凡, 朴元林. 基于网络药理学研究升陷汤治疗肺纤维化的作用机制[J]. 中医学, 2022, 11(3): 493-505. https://doi.org/10.12677/TCM.2022.113070

参考文献

[1] Spagnolo, P., Molyneaux, P.L., Bernardinello, N., et al. (2019) The Role of the Lung’s Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 20, 5618. [Google Scholar] [CrossRef] [PubMed]
[2] Raghu, G., Collard, H.R., Egan, J.J., et al. (2011) An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 183, 788-824. [Google Scholar] [CrossRef
[3] Kottmann, R.M., Hogan, C.M., Phipps, R.P., et al. (2009) Determinants of Initiation and Progression of Idiopathic Pulmonary Fibrosis. Respirology, 14, 917-933. [Google Scholar] [CrossRef] [PubMed]
[4] 张旭辉, 刘喜平, 等. 升陷汤对肺纤维化大鼠肺组织α-平滑肌肌动蛋白、肺表面活性蛋白D及TGF-β1/Smads通路蛋白表达的影响[J]. 中国中医药信息杂志, 2021, 28(4): 63-68.
[5] 郝伟欣, 董振华. 升陷汤加味治疗结缔组织病合并肺间质纤维化体会[J]. 中华中医药杂志, 2008, 23(8): 707-709.
[6] 马桂琴. 运用“象”思维辨治结缔组织病继发肺间质纤维化[J]. 中医杂志, 2013, 54(10): 884-885.
[7] Ru, J., Li, P., Wang, J., et al. (2014) TCMSP: A Database of Systems Pharmacology for Drug Discovery from Herbal Medicines. Journal of Cheminformatics, 6, 13. [Google Scholar] [CrossRef] [PubMed]
[8] Xu, X., Zhang, W., Huang, C., et al. (2012) A Novel Chemometric Method for the Prediction of Human Oral Bioavailability. International Journal of Molecular Sciences, 13, 6964-6982. [Google Scholar] [CrossRef] [PubMed]
[9] Safran, M., Dalah, I., Alexander, J., et al. (2010) GeneCards Version 3: The Human Gene Integrator. Database (Oxford), baq020. [Google Scholar] [CrossRef] [PubMed]
[10] (2019) UniProt: A Worldwide Hub of Protein Knowledge. Nucleic Acids Research, 47, D506-D515. [Google Scholar] [CrossRef] [PubMed]
[11] Otasek, D., Morris, J.H., Bouças, J., et al. (2019) Cytoscape Automation: Empowering Workflow-Based Network Analysis. Genome Biology, 20, 185. [Google Scholar] [CrossRef] [PubMed]
[12] 赵文清, 郑敏宇. 特发性肺纤维化的中西医治疗进展[J]. 中华中医药学刊, 2016, 34(2): 402-405.
[13] 李想, 常虹, 石松利, 等. 肺纤维化的中医病机及中医药治疗研究进展[J]. 中药药理与临床, 2021(1): 240-247.
[14] 张锡纯. 医学衷中参西录[M]. 太原: 山西科学技术出版社, 2009: 82.
[15] 杨胜利, 胡寒飞. 慢性阻塞性肺疾病急性加重期用升陷汤加味治疗的效果[J]. 中国继续医学教育, 2019, 11(16): 139-141.
[16] 蔡琳, 李理, 江丹. 黄芪注射液对肺纤维化小鼠肺组织上皮-间质转分化的影响[J]. 现代中西医结合杂志, 2017, 26(28): 3087-3089+103.
[17] 袁晓梅, 高新愿, 杨小花. 黄芪注射液治疗特发性肺纤维化的疗效[J]. 深圳中西医结合杂志, 2020, 30(6): 35-36.
[18] 黄霂晗, 韩佳, 徐昌君, 等. 黄芪甲苷对肺纤维化小鼠α-SMA、I型和III型胶原表达影响[J]. 辽宁中医药大学学报, 2019, 21(1): 47-50.
[19] 栾智华, 张东坡, 刘必旺, 等. 黄芪甲苷对肺纤维化小鼠VEGF/VEGFR2信号通路的影响[J]. 时珍国医国药, 2019, 30(7): 1611-1613.
[20] 杜全宇, 柳丽娟, 朱万婷, 等. 黄芪多糖对肺纤维化大鼠mTOR、p-S6、α-SMA的影响[J]. 亚太传统医药, 2020, 16(1): 13-17.
[21] 管淑红, 王智刚, 朱煜明, 等. 柴胡皂甙D对肺纤维化小鼠上皮-间质转化的干预作用及机制研究[J]. 重庆医学, 2018, 47(22): 2913-2916.
[22] Zhang, F., Zhan, Q., Gao, S., et al. (2014) Chemical Profile- and Pharmacokinetics-Based Investigation of the Synergistic Property of Platycodonis Radix in Traditional Chinese Medicine Formula Shengxian Decoction. Journal of Ethnopharmacology, 152, 497-507. [Google Scholar] [CrossRef] [PubMed]
[23] 张智琳, 梁迪思, 孔祥照, 等. 加用引经药桔梗对社区获得性肺炎患者炎症指标的影响[J]. 中医临床研究, 2019, 11(16): 77-79.
[24] 陈将, 章小敏, 叶爱菊, 等. 槲皮素抗肺纤维化的分子机制研究[J]. 中国中医药科技, 2018, 25(5): 666-669.
[25] Veith, C., Drent, M., Bast, A., et al. (2017) The Disturbed Redox-Balance in Pulmonary Fibrosis Is Modulated by the Plant Flavonoid Quercetin. Toxicology and Applied Pharmacology, 336, 40-48. [Google Scholar] [CrossRef] [PubMed]
[26] 许火龙, 聂磊, 李春玉, 等. 槲皮素抗纤维化机制的研究进展[J]. 微量元素与健康研究, 2021, 38(3): 70-73.
[27] 熊红, 江汉华, 杨开云. 银杏叶提取物对肺纤维化模型大鼠血清中TNF-α、IL-6表达的影响[J]. 时珍国医国药, 2012, 23(8): 2063-2064.
[28] 董洪亮, 刘乃国, 苗双, 等. 1,25-(OH)_2D_3对肺纤维化大鼠中PI3K、AKT、mTOR表达的影响及其机制研究[J]. 中国现代医学杂志, 2018, 28(19): 1-6.
[29] 李欣展. 血清VEGF、Leptin水平与特发性肺纤维化的相关性研究[D]: [硕士学位论文]. 济南: 山东大学, 2020.
[30] 崔园园. 特发性肺纤维化患者血清TGF-β1、STAT1表达水平及临床意义[D]: [硕士学位论文]. 济南: 山东大学, 2019.
[31] 刘玲, 何振华. PI3K/Akt信号通路与肺纤维化[J]. 微生物学免疫学进展, 2017, 45(6): 80-84.
[32] Rahimi, R.A. and Leof, E.B. (2007) TGF-Beta Signaling: A Tale of Two Responses. Journal of Cellular Biochemistry, 102, 593-608. [Google Scholar] [CrossRef] [PubMed]
[33] Cook, B.D., Ferrari, G., Pintucci, G., et al. (2008) TGF-beta1 Induces Rearrangement of FLK-1-VE-cadherin-beta-catenin Complex at the Adherens Junction through VEGF-Mediated Signaling. Journal of Cellular Biochemistry, 105, 1367- 1373. [Google Scholar] [CrossRef] [PubMed]
[34] 李琼, 郭丹, 加慧, 等. 灵菌红素对小鼠肺纤维化及其对Wnt/β-catenin信号通路的影响[J]. 解剖科学进展, 2020, 26(1): 105-108.
[35] Chen, X., Shi, C., Meng, X., et al. (2016) Inhibition of Wnt/β-Catenin Signaling Suppresses Bleomycin-Induced Pulmonary Fibrosis by Attenuating the Expression of TGF-β1 and FGF-2. Experimental and Molecular Pathology, 101, 22-30. [Google Scholar] [CrossRef] [PubMed]
[36] Li, S. and Zhang, B. (2013) Traditional Chinese Medicine Network Pharmacology: Theory, Methodology and Application. Chinese Journal of Natural Medicines, 11, 110-120. [Google Scholar] [CrossRef